儿童自身免疫性肝炎的诊治进展

张雪媛; 王建设

doi:10.3969/j.issn.1001-5256.2020.04.004

儿童自身免疫性肝炎的诊治进展

DOI: 10.3969/j.issn.1001-5256.2020.04.004

复旦大学附属儿科医院感染传染科

详细信息

中图分类号: R725.7
计量
- 文章访问数: 1624
- HTML全文浏览量: 46
- PDF下载量: 356
- 被引次数: 0
出版历程
- 收稿日期: 2020-02-02
- 出版日期: 2020-04-20

Advances in the diagnosis and treatment of pediatric autoimmune hepatitis

Department of Infectious Diseases,Children's Hospital of Fudan University

摘要

摘要: 自身免疫性肝炎（AIH）是一种进行性炎症性肝病,儿童AIH发病率近年来逐步上升。AIH可分为两种类型:抗核抗体和（或）平滑肌抗体和（或）抗可溶性肝抗原抗体阳性的AIH-1、抗肝-肾微粒体1型和（或）抗肝细胞溶质1型抗体阳性的AIH-2,AIH-2主要见于儿童。正常儿童少见自身抗体阳性,因此儿童AIH诊断时对自身抗体滴度的要求低于成人标准,但儿童AIH疾病进展比成人期更快,因此确诊后应该立即开始治疗。成人AIH诊断评分系统不适用于儿科患者,尤其不适于区分AIH和自身免疫性硬化性胆管炎。
- 肝炎,自身免疫性 /
- 儿童 /
- 免疫抑制剂 /
- 诊断 /
- 治疗学
Abstract: Autoimmune hepatitis( AIH) is a progressive inflammatory liver disease,and the incidence rate of pediatric AIH is gradually increasing in recent years. AIH can be classified into AIH-1( with positive antinuclear antibody and/or smooth muscle antibody and/or anti-soluble liver antigen antibody) and AIH-2( with positive liver-kidney microsomal type 1 antibody and/or anti-liver cytosol type 1 antibody),among which AIH-2 is mainly seen in children. Positive autoantibodies are rare in healthy children,and thus the requirements for autoantibody titer in the diagnosis of pediatric AIH are lower than the criteria for adults. Pediatric AIH progresses more rapidly than adult AIH,and treatment should be started immediately after confirmed diagnosis. Scoring systems for the diagnosis of AIH in adults are not applicable to pediatric patients and cannot be used to differentiate AIH from autoimmune sclerosing cholangitis.
- hepatitis,autoimmune /
- children /
- immunosuppressive agents /
- diagnosis /
- therapeutics

HTML全文

参考文献(63)

[1] JIMNEZ-RIVERA C,LING SC,AHMED N,et al. Incidence and characteristics of autoimmune hepatitis[J]. Pediatrics,2015,136(5):e1237-1248.

[2] MIELI-VERGANI G,VERGANI D. Budesonide for juvenile autoimmune hepatitis? Not yet[J]. J Pediatr,2013,163(5):1246-1248.

[3] MIELI-VERGANI G,VERGANI D,BAUMANN U,et al. Diagnosis and management of pediatric autoimmune liver disease:ESPGHAN hepatology committee position statement[J]. J Pediatr Gastroenterol Nutr,2018,66(2):345-360.

[4] ALVAREZ F,BERG PA,BIANCHI FB,et al. International autoimmune hepatitis group report:Review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol,1999,31(5):929-938.

[5] HENNES EM,ZENIYA M,CZAJA AJ,et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology,2008,48(1):169-176.

[6] HIEJIMA E,KOMATSU H,SOGO T,et al. Utility of simplified criteria for the diagnosis of autoimmune hepatitis in children[J]. J Pediatr Gastroenterol Nutr,2011,52(4):470-473.

[7] SEBODE M,HARTL J,VERGANI D,et al. Autoimmune hepatitis:From current knowledge and clinical practice to future research agenda[J]. Liver Int,2018,38(1):15-22.

[8] LIWINSKI T,SCHRAMM C. Autoimmune hepatitis-update on clinical management in 2017[J]. Clin Res Hepatol Gastroenterol,2017,41(6):617-625.

[9] CAO LL,ZHANG M,ZHU SS,et al. Clinical and pathological characteristics and outcome of 46 children with autoimmune hepatitis[J]. Chin J Pediatr,2019,57(1):40-45.(in Chinese)曹丽丽，张敏，朱世殊，等．儿童自身免疫性肝炎46例临床病理特点及疗效分析[J]．中华儿科杂志，2019,57(1):40-45.

[10] BAVEN-PRONK M,BIEWENGA M,van SILFHOUT JJ,et al.Role of age in presentation,response to therapy and outcome of autoimmune hepatitis[J]. Clin Transl Gastroenterol,2018,9(6):165.

[11] FOGEL R,COMERFORD M,CHILUKURI P,et al. Extrahepatic autoimmune diseases are prevalent in autoimmune hepatitis patients and their first-degree relatives:Survey study[J]. Interact J Med Res,2018,7(2):e18.

[12] GUO L,ZHOU L,ZHANG N,et al. Extrahepatic autoimmune diseases in patients with autoimmune liver diseases:A phenomenon neglected by gastroenterologists[J]. Gastroenterol Res Pract,2017,2017:2376231.

[13] FERRE EM,ROSE SR,ROSENZWEIG SD,et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy[J]. JCI Insight,2016,1(13):e88782.

[14] TERZIROLI BERETTA-PICCOLI B,MIELI-VERGANI G,VERGANI D. The clinical usage and definition of autoantibodies in immune-mediated liver disease:A comprehensive overview[J]. J Autoimmun,2018,95:144-158.

[15] VILLALTA D,GIROLAMI E,ALESSIO MG,et al. Autoantibody profiling in a cohort of pediatric and adult patients with autoimmune hepatitis[J]. J Clin Lab Anal,2016,30(1):41-46.

[16] VERGANI D,ALVAREZ F,BIANCHI FB,et al. Liver autoimmune serology:A consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group[J]. J Hepatol,2004,41(4):677-683.

[17] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of autoimmune hepatitis(2015)[J]. J Clin Hepatol,2016,32(1):9-22.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．自身免疫性肝炎诊断和治疗共识(2015)[J]．临床肝胆病杂志，2016,32(1):9-22.

[18] LIBERAL R,MIELI-VERGANI G,VERGANI D. Clinical significance of autoantibodies in autoimmune hepatitis[J]. J Autoimmun,2013,46:17-24.

[19] KIRSTEIN MM,METZLER F,GEIGER E,et al. Prediction of short-and long-term outcome in patients with autoimmune hepatitis[J]. Hepatology,2015,62(5):1524-1535.

[20] TERZIROLI BERETTA-PICCOLI B,MIELI-VERGANI G,VERGANI D. Serology in autoimmune hepatitis:A clinical-practice approach[J]. Eur J Intern Med,2018,48:35-43.

[21] MIAO Q,BIAN Z,TANG R,et al. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis[J]. Clin Rev Allergy Immunol,2015,48(2-3):226-235.

[22] de BOER YS,van NIEUWKERK CM,WITTE BI,et al. Assessment of the histopathological key features in autoimmune hepatitis[J]. Histopathology,2015,66(3):351-362.

[23] BALITZER D,SHAFIZADEH N,PETERS MG,et al. Autoimmune hepatitis:Review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria[J].Mod Pathol,2017,30(5):773-783.

[24] KUMARI N,KATHURIA R,SRIVASTAV A,et al. Significance of histopathological features in differentiating autoimmune liver disease from nonautoimmune chronic liver disease in children[J]. Eur J Gastroenterol Hepatol,2013,25(3):333-337.

[25] TUCKER SM,JONAS MM,PEREZ-ATAYDE AR. Hyaline droplets in Kupffer cells:A novel diagnostic clue for autoimmune hepatitis[J]. Am J Surg Pathol,2015,39(6):772-778.

[26] TINIAKOS DG,BRAIN JG,BURY YA. Role of histopathology in autoimmune hepatitis[J]. Dig Dis,2015,33(Suppl 2):53-64.

[27] GREGORIO GV,PORTMANN B,KARANI J,et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood:A 16-year prospective study[J]. Hepatology,2001,33(3):544-553.

[28] STRAVITZ RT,LEFKOWITCH JH,FONTANA RJ,et al. Autoimmune acute liver failure:Proposed clinical and histological criteria[J]. Hepatology,2011,53(2):517-526.

[29] di GIORGIO A,BRAVI M,BONANOMI E,et al. Fulminant hepatic failure of autoimmune aetiology in children[J]. J Pediatr Gastroenterol Nutr,2015,60(2):159-164.

[30] ARCOS-MACHANCOSES JV,MOLERA BUSOMS C,JULIO TATIS E,et al. Accuracy of the simplified criteria for autoimmune hepatitis in children:Systematic review and decision analysis[J]. J Clin Exp Hepatol,2019,9(2):147-155.

[31] European Association for the Study of the Liver. EASL clinical practice guidelines:Autoimmune hepatitis[J]. J Hepatol,2015,63(4):971-1004.

[32] HARRISON L,GLEESON D. Stopping immunosuppressive treatment in autoimmune hepatitis(AIH):Is it justified(and in whom and when)?[J]. Liver Int,2019,39(4):610-620.

[33] PNIEWSKA A,SOBOLEWSKA-PILARCZYK M,PAWOWSKA M. Evaluation of the effectiveness of treatment with prednisone and azathioprine of autoimmune hepatitis in children[J]. Prz Gastroenterol,2016,11(1):18-23.

[34] GREGORIO GV,PORTMANN B,KARANI J,et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood:A 16-year prospective study[J]. Hepatology,2001,33(3):544-553.

[35] GREGORIO GV,PORTMANN B,REID F,et al. Autoimmune hepatitis in childhood:A 20-year experience[J]. Hepatology,1997,25(3):541-547.

[36] MANNS MP,JAECKEL E,TAUBERT R. Budesonide in autoimmune hepatitis:The right drug at the right time for the right patient[J]. Clin Gastroenterol Hepatol,2018,16(2):186-189.

[37] PEISELER M,LIEBSCHER T,SEBODE M,et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2018,16(2):260-267. e1.

[38] WOYNAROWSKI M,NEMETH A,BARUCH Y,et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents[J]. J Pediatr,2013,163(5):1347-1353. e1.

[39] MACK CL,ADAMS D,ASSIS DN,et al. Diagnosis and management of autoimmune hepatitis in adults and children:2019practice guidance and guidelines from the American Association for the study of liver diseases[J]. Hepatology,2019.[Epub ahead of print]

[40] FRANULOVIC'OZ,RAJACIC'N,LESAR T,et al. Cyclosporine induced biochemical remission in childhood autoimmune hepatitis[J]. Coll Antropol,2012,36(3):973-979.

[41] NASTASIO S,SCIVERES M,MATARAZZO L,et al. Longterm follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine[J]. Dig Liver Dis,2019,51(5):712-718.

[42] de LEMOS-BONOTTO M,VALLE-TOVO C,COSTABEBER AM,et al. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment[J]. Eur J Gastroenterol Hepatol,2018,30(2):212-216.

[43] EFE C,TAII HA,YTTING H,et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis[J]. Dig Dis Sci,2018,63(5):1348-1354.

[44] SANTIAGO P,SCHWARTZ I,TAMARIZ L,et al. Systematic review with meta-analysis:Mycophenolate mofetil as a second-line therapy for autoimmune hepatitis[J]. Aliment Pharmacol Ther,2019,49(7):830-839.

[45] ZIZZO AN,VALENTINO PL,SHAH PS,et al. Second-line agents in pediatric patients with autoimmune hepatitis:A systematic review and meta-analysis[J]. J Pediatr Gastroenterol Nutr,2017,65(1):6-15.

[46] D'AGOSTINO D,COSTAGUTA A，LVAREZ F. Successful treatment of refractory autoimmune hepatitis with rituximab[J]. Pediatrics,2013,132(2):e526-e530.

[47] KAVCIC M,FISHER BT,SEIF AE,et al. Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children’s hospitals across the United States[J]. J Pediatr,2013,162(6):1252-1258,1258. e1.

[48] RAJANAYAGAM J,LEWINDON PJ. Infliximab as rescue therapy in paediatric autoimmune hepatitis[J]. J Hepatol,2013,59(4):908-909.

[49] AVERBUKH LD,WU GY. Role of biologics in the development of autoimmune hepatitis:A review[J]. J Clin Transl Hepatol,2018,6(4):402-409.

[50] KUROWSKI J,MELIN-ALDANA H,BASS L,et al. Sirolimus as rescue therapy in pediatric autoimmune hepatitis[J]. J Pediatr Gastroenterol Nutr,2014,58(1):e4-e6.

[51] NARKEWICZ MR,HORSLEN S,BELLE SH,et al. Prevalence and significance of autoantibodies in children with acute liver failure[J]. J Pediatr Gastroenterol Nutr,2017,64(2):210-217.

[52] RAMACHANDRAN J,SAJITH KG,PAL S,et al. Clinicopathological profile and management of severe autoimmune hepatitis[J]. Trop Gastroenterol,2014,35(1):25-31.

[53] MARTIN SR,ALVAREZ F,ANAND R,et al. Outcomes in children who underwent transplantation for autoimmune hepatitis[J]. Liver Transpl,2011,17(4):393-401.

[54] DENEAU M,JENSEN MK,HOLMEN J,et al. Primary sclerosing cholangitis,autoimmune hepatitis,and overlap in Utah children:Epidemiology and natural history[J]. Hepatology,2013,58(4):1392-1400.

[55] JOSSEN J,ANNUNZIATO R,KIM HS,et al. Liver transplantation for children with primary sclerosing cholangitis and autoimmune hepatitis:UNOS database analysis[J]. J Pediatr Gastroenterol Nutr,2017,64(4):e83-e87.

[56] MONTANO-LOZA AJ,BHANJI RA,WASILENKO S,et al.Systematic review:Recurrent autoimmune liver diseases after liver transplantation[J]. Aliment Pharmacol Ther,2017,45(4):485-500.

[57] PUUSTINEN L,BOYD S,ARKKILA P,et al. Histologic surveillance after liver transplantation due to autoimmune hepatitis[J]. Clin Transplant,2017,31(5):e12936.

[58] STIRNIMANN G,EBADI M,CZAJA AJ,et al. Recurrent and de novo autoimmune hepatitis[J]. Liver Transpl,2019,25(1):152-166.

[59] THEOCHARIDOU E,HENEGHAN MA. Con:Steroids should not be withdrawn in transplant recipients with autoimmune hepatitis[J]. Liver Transpl,2018,24(8):1113-1118.

[60] KALRA A,BURTON JR Jr,FORMAN LM. Pro:Steroids can be withdrawn after transplant in recipients with autoimmune hepatitis[J]. Liver Transpl,2018,24(8):1109-1112.

[61] DENEAU M,BOOK LS,GUTHERY SL,et al. Outcome after discontinuation of immunosuppression in children with autoimmune hepatitis:A population-based study[J]. J Pediatr,2014,164(4):714-719. e2.

[62] BOZZINI AB,NEDER L,SILVA CA,et al. Decreased healthrelated quality of life in children and adolescents with autoimmune hepatitis[J]. J Pediatr(Rio J),2019,95(1):87-93.

[63] van den BRAND FF,van der VEEN KS,de BOER YS,et al.Increased mortality among patients with vs without cirrhosis and autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2019,17(5):940-947. e2.

施引文献

资源附件(0)

访问统计